Halozyme Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Leadership changes can affect company strategy and operations, which matters to investors monitoring management stability.
Quarterly earnings show whether the company is making money and growing, helping you decide if it's a good investment.
Stockholders voting on compensation and auditors ensures executives are paid fairly and finances are checked honestly.
New CFO from Johnson & Johnson brings experience; his $7.2 million signing bonus shows the company values his leadership.
Changing voting rules on removing directors affects how much power shareholders have over company leadership decisions.
Interim CFO appointment fills leadership gap while company searches for permanent finance leader to manage money.
Stocky reads Halozyme Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Halozyme Therapeutics, Inc.'s most recent tracked filing was a 8-K on 2 Jul 2026: Chief Operating Officer Cortney Caudill departs company.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.